The trend is bullish now. French investors are back now maybe because of 2 gene covid 19 molecular test that gives us opportunity to reimburse tests in France.
Other companies are conducting clinical trial similar to our drug BT 197 -Acumapimod for the treatment of Covid 19 patients. Possible treatment that may enter phase 3 clinical trial. Imho
Dyor, If the Glycotest Hcc panel’s validation is approved and launched commercially, It would bring more than £100 million revenue in the next 2 years . Hopefully we would hear updates soon. Before u invest please dyor.